Ovarian Cancer Coverage from Every Angle

Susana M. Campos, MD, MPH, on the Role of PARP Inhibitors in the Treatment Landscape of Ovarian Cancer

Posted: Thursday, April 26, 2018

Susana M. Campos, MD, MPH, of Dana-Farber Cancer Institute, discusses the use of PARP inhibitors in ovarian cancer and the implications for treatment going forward.

By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.